2000 Study by Merck Showed Vioxx Risk: Results Not Given to FDA – Star Ledger Sun, 3 Jul 2005 News reports reveal that Merck failed to disclose Vioxx lethal effects to the FDA. Sheldon Krimsky, a science policy expert at Tufts University states: “if there was evidence the drug was…
January 7, 2002 FYI MAD IN AMERICA (Perseus Press), a new book by Robert Whitaker, a prize winning science journalist, is sure to cause a stir. Whitaker holds psychiatry’s feet to the fire by examining the evidence in the professional psychiatric literature, FDA documents, published treatment outcome studies–including the World…
Studies Link Zyprexa to Diabetes & Deaths_Balt Sun Thu, 20 Mar 2003 Eli Lilly’s best selling drug, olanzapine (Zyprexa), originally approved for schizophrenia, then for bi-polar disorder, is prescribed widely. But the drug has been shown to produce early onset diabetes, severe hyperglycemia–and deaths. Adolescents and young adults appear to…
AHRP Alliance for Human Research Protection AHRP Speaks Out Return to Home PageAHRP Speaks Out Press ReleasesOctober 29, 2001 FYI Widely disparate perspectives are presented in an article in the Maryland Daily Record re: The Court of Appeals of Maryland decision (Gimes v Kennedy Krieger Institute, Aug 16, 2001). That…
Widely disparate perspectives are presented in an article in the Maryland Daily Record re: The Court of Appeals of Maryland decision (Gimes v Kennedy Krieger Institute, Aug 16, 2001). That 6-to-1 landmark decision severely criticized the practice of exposing healthy children to risks of harm in health related research. Children, we must bear in mind, are powerless to exercise that inviolable human right, the right to refuse to assume risks for research.
Will this decision undermine the legitimacy of research that puts healthy children at risk in clinical trials? AHRP believes it will, and that the decision will be sustained by other courts in other states.
October 1, 2001 Following the August 16, 2001 landmark decision* of the Maryland Court of Appeals, the Alliance for Human Research Protection (AHRP) became interested in the case involving exposure of children to lead paint. We were particularly drawn to the Court’s clear and unambiguous recognition of the rights of…
Following the August 16, 2001 landmark decision of the Maryland Court of Appeals, the Alliance for Human Research Protection (AHRP) became interested in the case involving exposure of children to lead paint. We were particularly drawn to the Court’s clear and unambiguous recognition of the rights of children and their families to appropriate safeguards in medical research settings.
http://www.courts.state.md.us/opinions/coa/2001/128a00.pdf
Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support of the Court’s ruling against Kennedy Krieger Institute for exposing children to lead poison in an experiment. The Court of Appeals Decision Validates AHRP’s Stand Against Using Children in Harmful Research Experiments.
Research Protection for Children AHRP Return to Home Page Research Protection for Children September 21, 2001Human values vs. $$$:Children at Risk in Research FYI A consortium of powerful research lobbyists led by Johns Hopkins University are demanding that the Maryland Court of Appeals modify its ruling in the University’s…
A landmark decision by Maryland’s highest court, the Court of Appeals of Maryland, is a victory for the human rights of children. The decision affirms the responsibility of parents, the government, researchers and institutional review boards (IRB) to protect children from non-therapeutic experiments that may put their health at risk.
A group of patient and social justice advocates plan to form an Alliance for Human Research Protection to provide oversight on clinical research from laypersons’ point of view, says John H. Noble Jr., a founder and professor of social justice at the Catholic University of America. He lambastes Internal Review Boards (IRBs) designed to protect human subjects as agents of institutions "who are hustling the bucks" from industry and other sources. Noble says IRBs need to be "severed from research institutions" and provided adequate resources as part of the accepted overhead costs of conducting clinical trials.
AHRP Alliance for Human Research Protection AHRP Speaks Out Return to Home PageAHRP Speaks Out Press ReleasesAugust 17, 2001 Following the August 16, 2001 landmark decision* of the Maryland Court of Appeals, the Alliance for Human Research Protection (AHRP) became interested in the case involving exposure of children to…
